Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1051 to 1065 of 7691 results

  1. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)

    Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.

  2. Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)

    Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.

  3. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  4. Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.

  5. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

  6. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

  7. Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) (TA701)

    NICE is unable to make a recommendation on crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older because Pfizer withdrew its evidence submission.

    Sections for TA701

  8. Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

    Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.

  9. Avelumab for untreated metastatic Merkel cell carcinoma (TA691)

    Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults.

  10. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

    Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

  11. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

  12. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing venous thromboembolism after hip or knee replacement surgery in adults.

  13. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

  14. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

  15. Routine antenatal anti-D prophylaxis for women who are rhesus D negative (TA156)

    Evidence-based recommendations on routine anti-D prophylaxis for women who are rhesus D negative.